Increased MAO-A activity has been associated with depression (Meyer et al., 2006) and several FDA-approved MAO-A inhibitors have been used for the treatment of depression and anxiety (Finberg and Rabey, 2016). Here, MAOA is linked to depressive symptom measurement.